Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ELI-002||ELI002|ELI 002||ELI-002 is a peptide-based cancer vaccine consisting of KRAS mutant peptides admixed with the adjuvant AMP CpG-7909, potentially resulting in activation of the antitumor immune response against NRAS and KRAS expressing tumor cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04853017||Phase Ib/II||ELI-002||A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumor (AMPLIFY-201)||Recruiting||USA||0|